Janning et al. reported that in non-small cell lung cancer, the detection of the PD-L1 level of circulating tumor cells can predict the patient’s response to PD-L1 inhibitors, and the increased expression of PD-L1 levels of circulating tumor cells in patients after treatment can reflect the patient’s response The resistance of PD-L1 (20). This evidence concerns the gene CD274 and non-small cell lung carcinoma.